Effect of ACE [angiotensin-converting enzyme] inhibitor plus high dose candesartan [candesartan cilexetil] on BNP [brain natriuretic peptide] and inflammation in patients with LV [left ventricular] dysfunction: impact of renin-angiotensin-aldosterone system genetic polymorphisms.

Trial Profile

Effect of ACE [angiotensin-converting enzyme] inhibitor plus high dose candesartan [candesartan cilexetil] on BNP [brain natriuretic peptide] and inflammation in patients with LV [left ventricular] dysfunction: impact of renin-angiotensin-aldosterone system genetic polymorphisms.

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Jul 2011

At a glance

  • Drugs Candesartan cilexetil (Primary)
  • Indications Chronic heart failure; Left ventricular dysfunction
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Jul 2011 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
    • 20 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top